Medication Profile · Updated November 2026

Wegovy (Semaglutide 2.4mg): Cost, Weight Loss Data, and How to Get It in 2026

Wegovy is semaglutide built specifically for weight loss. Same molecule as Ozempic, but at a higher dose and with an FDA approval that actually says "chronic weight management" on the label. It also has a heart risk reduction indication for adults with heart disease and overweight or obesity, based on the SELECT trial. And since December 2025 there is a daily pill version. Here is the full picture for anyone considering Wegovy in 2026.

Quick Facts

How Wegovy Works

Wegovy is a GLP-1 receptor agonist. It mimics a naturally occurring hormone called glucagon-like peptide-1 that plays a role in appetite regulation and blood sugar control. The mechanism is the same as Ozempic (they are literally the same molecule), but Wegovy is dosed higher and approved for a different purpose.

Here is what semaglutide does in your body:

1. Suppresses appetite. It acts on GLP-1 receptors in the hypothalamus, the part of your brain that regulates hunger. You feel full faster and experience fewer food cravings between meals.
2. Slows digestion. Food moves through your stomach more slowly, which keeps you satisfied longer after eating and reduces post-meal blood sugar spikes.
3. Improves insulin sensitivity. Your body handles blood sugar more efficiently, which is why semaglutide was originally developed for diabetes.
4. Cardiovascular protection. Among weight-loss drugs, this is Wegovy’s edge. Zepbound’s label has no heart risk reduction indication. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with overweight or obesity and existing cardiovascular disease who did not have diabetes.

The cardiovascular benefit is a big deal. It is the reason Wegovy has an additional FDA-approved indication for reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. This can also help with insurance coverage, which I cover below.

For a breakdown of how single-action GLP-1s (like semaglutide) compare to dual-action drugs (like tirzepatide in Mounjaro), see our Mounjaro vs Ozempic comparison.

Dosing Schedule

Wegovy uses a gradual dose escalation to minimize GI side effects. Per the Wegovy label, you start at 0.25 mg and step up every 4 weeks, reaching 2.4 mg at week 17. If you do not tolerate a step, the label says to consider delaying the next increase by 4 weeks.

Injectable Wegovy

The label maintenance dose for weight reduction is 2.4 mg, or 1.7 mg if needed. For people who tolerate 2.4 mg for at least 4 weeks and need more weight reduction, the label allows an increase to a maximum of 7.2 mg (Wegovy HD). Ozempic maxes out at 2 mg.

Label safety points: Wegovy is not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Stop it if you become pregnant, and stop at least 2 months before a planned pregnancy. Seek care for severe stomach pain that does not go away. If you miss 2 or more weekly doses in a row, the label says to restart at a lower dose, so ask your prescriber before resuming.

Oral Wegovy (Pill)

Wegovy tablets were added to the Wegovy label in December 2025. You start at 1.5 mg daily and step up every 30 days through 4 mg and 9 mg to a 25 mg maintenance dose. In the OASIS 4 trial, oral semaglutide 25 mg produced 13.6% weight loss at 64 weeks vs 2.2% on placebo.

The oral version requires specific timing: take it in the morning on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other oral medications. NovoCare lists the pill at $149 a month for 1.5 mg, $199 for 4 mg and $299 for 9 mg or 25 mg.

For a detailed comparison of the pill and injection, including absorption differences and real-world considerations, read our Wegovy pill vs injection guide.

Weight Loss Results

Wegovy has the most weight loss clinical trial data of any GLP-1 medication. Here are the key numbers.

STEP 1 Trial (the headline study)

Published in the New England Journal of Medicine (2021). Studied semaglutide 2.4 mg in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. No diabetes.

Results at 68 weeks:

• Semaglutide 2.4 mg: 14.9% body weight loss (average)
• Placebo: 2.4% body weight loss
• Half of participants (50.5%) lost at least 15% of body weight
• 86.4% of semaglutide participants lost at least 5% of body weight (STEP 1)

What that looks like in practice: For a 220 lb person, 14.9% equals roughly 33 lbs over about 16 months. The top responders in the trial lost considerably more.

STEP 2 (patients with type 2 diabetes)

Weight loss was lower in people with type 2 diabetes: 9.6% at 68 weeks vs 3.4% on placebo (STEP 2). People with diabetes tend to lose less weight on these medications compared to non-diabetic patients.

STEP 3 (with intensive behavioral therapy)

When combined with intensive behavioral therapy (dietary counseling, exercise coaching, calorie restriction), weight loss was 16.0% at 68 weeks vs 5.7% on placebo (STEP 3). This was a separate trial, so it cannot be compared directly with STEP 1.

STEP 5 (long-term, 2 years)

Participants had 15.2% body weight loss at 104 weeks (2 years) vs 2.6% on placebo (STEP 5), showing the effect held with continued use.

SELECT Trial (cardiovascular outcomes)

This is the trial that changed Wegovy’s position in the market. Published in 2023, SELECT studied semaglutide 2.4 mg in 17,604 adults with obesity or overweight who had established cardiovascular disease but did not have diabetes.

Key findings:

• 20% reduction in the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke
• 6.5% of the semaglutide group had a primary event vs 8.0% on placebo, over a mean follow-up of 39.8 months

The SELECT data gave Wegovy an additional FDA indication for cardiovascular risk reduction, which some insurers now use when deciding coverage for people with heart disease.

How does this compare to other GLP-1s?

Wegovy’s 14.9% average weight loss is strong, but tirzepatide (Mounjaro/Zepbound) showed more. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss vs 13.7% for semaglutide 2.4 mg over 72 weeks. The tradeoff is that Wegovy has the heart risk reduction indication and a pill, while tirzepatide is injection-only and its label has no such indication for people without diabetes. See our full comparison for the complete breakdown.

From tracking my own body composition on Mounjaro with DEXA scans, I have learned that the total weight loss number only tells part of the story. How much of that loss is fat vs. muscle matters enormously for long-term health. Our fat loss vs weight loss guide and exercise guide cover this in depth.

What Wegovy Costs in 2026

Wegovy is the most expensive semaglutide option at list price, but the total cost varies wildly depending on your insurance, eligibility for savings programs, and whether you consider compounded alternatives.

Brand-Name Wegovy

Self-pay patients can buy Wegovy pens from NovoCare for $349 per month at any dose from 0.25 mg to 2.4 mg, and $399 for Wegovy HD 7.2 mg (checked Nov 4, 2026). New patients pay $199 a month for the first two fills of 0.25 mg or 0.5 mg, through December 31, 2026. The retail list price is far higher, and Novo has announced it will cut it to $675 a month on January 1, 2027. Our 2026 GLP-1 Cash-Pay Pricing Index tracks more options.

Novo Nordisk savings programs: Through NovoCare, patients with commercial insurance that covers Wegovy may pay as little as $25 a month, with savings capped at $100 a month. Government plan members are excluded.

With insurance: Coverage varies widely. Many employer plans still exclude weight-loss drugs. Medicare Part D excludes drugs used only for weight loss, but some plans cover Wegovy for its heart risk reduction indication. Our GLP-1 insurance coverage guide and Medicare coverage guide detail how to get approved.

Compounded Semaglutide

Compounded semaglutide is not “compounded Wegovy” and is not FDA-approved. FDA declared the semaglutide shortage resolved on February 21, 2025, and the grace periods for compounders ended by May 22, 2025. Programs we checked listed about $125 to $297 a month on November 4, 2026, which is close to Wegovy’s $349 self-pay price.

The important caveat: FDA does not review compounded drugs for safety, effectiveness or quality, and it has received reports of hospitalizations tied to dosing errors with compounded semaglutide. The active ingredient is the same, but the manufacturing, quality control, and formulation come from compounding pharmacies rather than Novo Nordisk. Read our compounded vs brand-name guide for the full breakdown of risks and tradeoffs.

Cost Comparison Summary

For a complete breakdown of every pricing path, see our cheapest GLP-1 online guide and GLP-1 without insurance guide.

Where to Get Semaglutide Online

If you want brand-name Wegovy, you need a prescription from your doctor or a telehealth clinician, and you can fill it at a retail pharmacy or through NovoCare home delivery. These telehealth providers listed prices on their own pages when we checked on November 4, 2026.

For the complete provider directory with filtering by state, medication type, and price, visit our provider comparison page.

Common Side Effects

Wegovy’s side effect profile is the same as Ozempic’s, because it is the same drug. The frequency and intensity can differ at higher doses (especially 1.7 mg and 2.4 mg), where GI symptoms tend to be more pronounced.

Most common (10% or more of patients on 2.4 mg in the trials on the label):

• Nausea (44% vs 16% on placebo, mostly in early weeks and after dose increases)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Abdominal pain (20%)
• Headache (14%)
• Fatigue (11%)

Less common but notable:

• Dizziness
• Injection site reactions
• Acid reflux (GERD)

Serious but rare:

• Pancreatitis (severe abdominal pain that does not go away warrants immediate medical attention)
• Gallbladder problems and gallstones
• Kidney injury, typically secondary to dehydration from vomiting/diarrhea
• Increased heart rate (a small but consistent finding in trials, mean increases of 1 to 4 beats per minute)

Boxed warning: Like all semaglutide products, Wegovy carries a boxed warning about thyroid C-cell tumors found in animal studies. Not confirmed in humans, but the medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Managing side effects: The dose escalation schedule exists specifically to reduce GI side effects. For most people, nausea and digestive issues ease after the first weeks at each dose. Eating smaller meals, staying hydrated, and avoiding high-fat foods all help. For a month-by-month timeline of what to expect (and what actually worked for me on Mounjaro), see our GLP-1 side effects guide.

Wegovy vs. Related Medications

Wegovy vs. Ozempic: Same molecule (semaglutide), same manufacturer (Novo Nordisk). Ozempic is approved for type 2 diabetes with doses up to 2 mg. Wegovy is approved for weight management with doses up to 2.4 mg, or 7.2 mg with Wegovy HD. If your primary goal is weight loss, Wegovy is the version that was designed and tested for that purpose. Full Ozempic profile. I compare the diabetes and weight-loss dose ranges side by side in type 2 diabetes vs weight loss GLP-1 doses.

Wegovy vs. Zepbound: This is the real comparison that matters in 2026. Zepbound (tirzepatide) works on two receptors (GIP + GLP-1) vs. Wegovy’s one (GLP-1 only). Zepbound showed more weight loss in the head-to-head SURMOUNT-5 trial (20.2% vs 13.7%). Wegovy has the heart risk reduction indication from SELECT and a pill. Zepbound has a sleep apnea indication on its label. Self-pay, Zepbound KwikPens run $299 to $449 a month vs $349 for Wegovy pens. Your best option depends on your specific health profile and insurance situation. Full comparison.

Wegovy vs. Compounded Semaglutide: Brand-name Wegovy pens cost $349/month self-pay through NovoCare. Compounded semaglutide programs we checked listed about $125 to $297/month. The active ingredient is the same, but compounded products have not been through FDA review as finished medications. Compounded vs brand-name guide.

Wegovy Pill vs. Wegovy Injection: The daily pill, on the label since December 2025, offers a needle-free option. Absorption and bioavailability differ from the injectable form, and the pill requires specific timing around meals. We cover the full comparison in our Wegovy pill vs injection guide. For a broader look at oral vs. injectable GLP-1s, see our oral vs injectable guide.

Frequently Asked Questions

What we checked

This AI-assisted public-source desk check reviewed the Wegovy and Zepbound prescribing information, the FDA approval record and compounding pages, the STEP 1, STEP 2, STEP 3, STEP 5, STEP 1 extension, SELECT, SURMOUNT-5 and OASIS 4 trial publications, NovoCare’s Wegovy price pages, Novo Nordisk’s list price announcement, and the MEDVi and Ro pricing pages on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.

Related Resources

• Mounjaro vs Ozempic vs Wegovy vs Zepbound (2026)
• Wegovy Pill vs Injection: Which One to Choose
• Oral vs Injectable GLP-1 Medications
• Cheapest Way to Get GLP-1 Medications Online
• GLP-1 Side Effects: Month by Month Guide
• GLP-1 Insurance Coverage Guide
• GLP-1 Medicare Coverage in 2026
• Compounded vs Brand-Name GLP-1